AbCellera announces positive Phase 2 results for menopause drug ABCL635
AbCellera announced positive top-line Phase 2 results for ABCL635, a GPCR-targeting antibody for moderate-to-severe vasomotor symptoms, showing best-in-class reductions in frequency and severity after a single dose. The stock rose 20% pre-market on the news.
Detected & updated continuously · Source: Nebula
Story subjects
Sources
@JackPrescottX
$ABCL 🚨 AbCellera announces positive top line ph2 results for ABCL635, a GPCR targeting antibody: - Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single dose - ABCL635 significantly improved https://t.co/EQ6n8lx1rw
@Volume_Stocks
Pre-Market Update ⦿ $ABCL up 20%; Phase 2 menopause drug hit primary endpoints. ⦿ $ONDS up 4%; no fresh news — earnings Th after defense contract wins. ⦿ $AAOI up 4%; extending post-earnings rally on AI transceiver demand. ⦿ $SMCI up 4%; AI-chip rally ahead of Tuesday https://t.co/GOY4MTjfuS